Natera reported a strong third quarter with a 63.9% increase in total revenue to $439.8 million, driven by a 64.4% increase in product revenue. The company also saw improvements in gross margin and processed more tests compared to the same period last year.
Total revenue increased by 63.9% to $439.8 million compared to Q3 2023.
Product revenue increased by 64.4% to $436.1 million compared to Q3 2023.
Approximately 775,800 tests were processed in Q3 2024.
Net loss decreased to $31.6 million, or ($0.26) per diluted share, compared to a net loss of $109.0 million in Q3 2023.
Natera anticipates 2024 total revenue of $1.61 billion to $1.64 billion; 2024 gross margin to be approximately 58% to 61% of revenues; selling, general and administrative costs to be approximately $775 million to $825 million; research and development costs to be $375 million to $400 million; and net cash inflow to be $50 million to $75 million